Experiences in immune reconstitution. The rationale for interleukin-2 administration to HIV-infected individuals

Journal of Biological Regulators and Homeostatic Agents

Volumn 11, Issue 1-2, 1997, Pages 74-78

  Ghezzi, S ^a   Vicenzi, E ^a   Soldini, L ^a   Tambussi, G ^a   Murone, M ^a   Lazzarin, A ^a   Poli, G ^a  

^a SAN RAFFAELE HOSPITAL   (Italy)

Author keywords

CD4; CD8; Cytokines; HIV; IL 2; Immunreconstitution

Indexed keywords

CD4 ANTIGEN; CYTOKINE; INTERLEUKIN 2; RECOMBINANT INTERLEUKIN 2;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; CLINICAL PROTOCOL; CLINICAL TRIAL; CONFERENCE PAPER; HELPER CELL; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; MACROPHAGE; OPPORTUNISTIC INFECTION; T LYMPHOCYTE; VIRUS REPLICATION;

HUMAN IMMUNODEFICIENCY VIRUS;

EID: 0030832841     PISSN: 0393974X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (47)

1. Morgan DA, Ruscetti FW, Gallo RC. Selective in vitro growth of T lymphocytes from normal human bone marrows. Science 1976; 193: 1007-8.
2. Gillis S, Smith KA, Long term culture of tumour-specific cytotoxic T cells. Nature 1977; 268: 154-6.
3. Smith KA. T-cell growth factor. Immunol Rev 1980 51: 337-57.
4. Malek TR, Robb RJ, Shevach EM. Identification and initial characterization of a rat monoclonal antibody reactive with the murine interleukin 2 receptor-ligand complex. Proc Natl Acad Sci USA 1983; 80: 5694-8.
5. Watson J, Gillis S, Marbrook J, Mochizuki D, Smith KA. Biochemical and biological characterization of lymphocyte regulatory molecules. I. Purification of a class of murine lymphokines. J Exp Med 1979; 150: 849-61.
6. Robb RJ, Munck A, Smith KA. T cell growth factor receptors. Quantitation, specificity, and biological. J Exp Med 1981; 154: 1455-74.
7. Depper JM, Leonard WJ, Robb RJ, Waldmann TA, Greene WC. Blockade of the interleukin-2 receptor by anti-Tac antibody: inhibition of human lymphocyte activation. J Immunol 1983; 131:690-6.
8. Cheever MA, Greenberg PD, Fefer A, Gillis S. Augmentation of the anti-tumor therapeutic efficacy of long-term cultured T lymphocytes by in vivo administration of purified interleukin 2. J Exp Med 1982; 155: 968-80.
9. Rosenberg SA, Mule JJ, Spiess PJ, Reichert CM, Schwarz SL. Regression of established pulmonary metastases and subcutaneous tumor mediated by the systemic administration of high-dose recombinant interleukin 2. J Exp Med 1985; 161: 1169-88.
10. Rosenberg SA. Combined modality therapy of cancer. What is it and when does it work? N Engl J Med 1986; 312: 1512-4.
11. Taniguchi T, Matsui H, Fujita T, et al. Structure and expression of a cloned cDNA for human interleukin-2. Nature 1983; 302: 305-10.
12. Rook AH, Masur H, Lane HC, et al. Quinnan GV Jr. Interleukin-2 enhances the depressed natural killer and cytomegalovirus-specific cytotoxic activities of lymphocytes from patients with the acquired immune deficiency syndrome. J Clin Invest 1983; 72: 398-403.
13. Lane HC, Depper JM, Greene WC, Whalen G, Waldmann TA, Fauci AS. Qualitative analysis of immune function in patients with the acquired immunodeficiency syndrome. Evidence for a selective defect in soluble antigen recognition. New Engl J Med 1985; 313: 79-84.
14. Ammar A, Cibert C, Bertoli AM, Tsilivakos V, Jasmin C, Georgoulias V. Biological and biochemical characterization of a factor produced spontaneously by adherent cells of human immunodeficiency virus-infected patients inhibiting interleukin-2 receptor alpha chain (Tac) expression on normal T cells. J Clin Invest 1991; 87: 2048-55.
15. Fernandez-Cruz E, Gelpi E, Longo N, et al Increased synthesis and production of prostaglandin E2 by monocytes from drug addicts with AIDS. AIDS 1989; 3: 91-6.
16. Clerici M, Hakim FT, Venzon DJ, et al. Changes in interleukin-2 and interleukin-4 production in asymptomatic, human immunodeficiency virus-seropositive individuals. J Clin Invest 1993; 91:759-65.
17. Ciardi M, Sharief MK, Noori MA, et al. Intrathecal synthesis of interleukin-2 and soluble IL-2 receptor in asymptomatic HIV-1 seropositive individuals. Correlation with local production of specific IgM and IgG antibodies. J Neurol Sci 1993; 115: 117-22.
18. Emilie D, Peuchmaur M, Maillot MC, et al. Production of interleukins in human immunodeficiency virus-1-replicating lymph nodes. J Clin Invest 1990; 86: 148-59.
19. Jacobson MA, De Gruttola V, Reddy M, et al. The predictive value of changes in serologic and cell markers of HIV activity for subsequent clinical outcome in patients with asymptomatic HIV disease treated with zidovudine. AIDS 1995; 9: 727-34.
20. Honda M, Kitamura K, Matsuda K, et al. Soluble IL-2 receptor in AIDS. Correlation of its serum level with the classification of HIV-induced diseases and its characterization J Immunol 1989; 142: 4248-55.
21. Chehimi J, Starr SE, Frank I, et al. Natural killer (NK) cell stimulatory factor increases the cytotoxic activity of NK cells from both healthy donors and human immunodeficiency virus-infected patients. J Exp Med 1992; 175: 789-96.
22. Poli G, Introna M, Zanaboni F, et al. Natural killer cells in intravenous drug abusers with lymphadenopathy syndrome. Clin Exp Immunol 1985; 62: 128-135.
23. Pantaleo G, Koenig S, Baseler M, Lane HC, Fauci AS. Defective clonogenic potential of CD8+ T lymphocytes in patients with AIDS. Expansion in vivo of a nonclonogenic CD3+CD8+DR+CD25- T cell population. J Immunol 1990; 144: 1696-704.
24. Gallo RC, Sann PS, Gelmann EP, et al. Isolation of human T-cell leukemia virus in acquired immune deficiency syndrome (AIDS). Science 1983; 220: 865-7.
25. Barre-Sinoussi F, Chermann JC, Rey F, et al. Isolation of a T-lymphotropic retrovirus from a patient at risk for acquired immune deficiency syndrome (AIDS). Science 1983; 220: 868-71.
26. Folks TM, Kelly J, Benn S, et al. Susceptibility of normal human lymphocytes to infection with HTLVIII/LAV. J Immunol 1986; 136: 4049-53.
27. Bukrinsky MI, Stanwick TL, Dempsey MP, Stevenson M. Quiescent T lymphocytes as an inducible virus reservoir in HIV-1 infection. Science 1991; 254: 423-7.
28. Gruters RA, Otto SA, Al BJ, et al. Non-mitogenic T cell activation signals are sufficient for induction of human immunodeficiency virus transcription. Eur J Immunol 1991; 21: 167-72.
29. Zack JA, Arrigo SJ, Weitsman SR, Go AS, Haislip A, Chen IS. HIV-1 entry into quiescent primary lymphocytes: molecular analysis reveals a labile, latent viral structure. Cell 1990; 61: 213-22.
30. Tsunetsugu-Yokota Y, Honda M. Effect of cytokines on HIV release and IL-2 receptor expression in monocytic cell lines. J Acquir Immun Def Synd Hum Retrovir 1990; 3: 511-6.
31. Kobayashi N, Hamamoto Y, Koyanagi Y, Chen IS, Yamamoto N. Effect of interleukin-1 on the augmentation of human immunodeficiency. Bioch Bioph Res Comm 1989; 165: 715-21.
32. Hazan U, Thomas D, Alcami J, et al. Stimulation of a human T-cell clone with anti-CD3 or tumor necrosis factor induces NF-kappa B translocation but not human immunodeficiency virus 1 enhancer-dependent transcription. Proc Natl Acad Sci USA 1990 87: 7861-5.
33. Poli G, Kinter A, Justement JS, et al. Tumor necrosis factor α functions in an autocrine manner in the induction of human immunodeficiency virus expression. Proc Natl Acad Sci USA 1990; 87: 782-5.
34. Goletti, D, Kinter, AL, Hardy, EC, Poli, G, Fauci, AS. Modulation of endogenous interleukin IL-1β and IL-1 receptor antagonist results in opposing effects on HIV expression in chronically infected monocytic cells. J Immunol 1996; 156: 3501-8.
35. Kinter AL, Poli G, Fox L, Hardy E, Fauci AS. HIV replication in IL-2-stimulated peripheral blood mononuclear cells is driven in an autocrine/paracrine manner by endogenous cytokines. J. Immunol 1995; 154: 2448-59.
36. Ramilo O, Bell KD, Uhr JW, Vitetta ES. Role of CD25+ and CD25-T cells in acute HIV infection in vitro. J Immunol 1993; 150: 5202-8.
37. Finberg RW, Wahl SM, Allen JB, et al. Selective elimination of HIV-1 infected cells with an interleukin-2 receptor-specific cytotoxin. Science 1991; 252: 1703-5.
38. Bell KD, Ramilo O, Vitetta ES. Combined use of an immunotoxin and cyclosporine to prevent both activated and quiescent peripheral blood T cells from producing type 1 human immunodeficiency virus. Proc Natl Acad Sci USA 1993; 90: 1411-5.
39. Kinter AL, Bende SM, Hardy EC, Jackson R, Fauci AS. 'Interleukin-2 induces CD8-mediated suppression of HIV replication in CD4+ T cells and this effect overrides its ability to stimulate virus expression. Proc Natl Acad Sci USA 1995; 92: 10985-9.
40. Levy JA, Mackewicz CE, Barker E. Controlling HIV pathogenesis: the role of noncytotoxic anti-HIV response of CD8+ T cells. Immunol Today 1995; 17: 217-24.
41. Teppler H, Kaplan G, Smith K, et al. Efficacy of low doses of the polyethylene glycol derivative of interleukin-2 in modulating the immune response of patients with human immunodeficiency virus type 1 infection. J Infect Dis 1993; 167: 291-8.
42. McElrath MJ, Kaplan G, Burkhardt RA, Cohn ZA. Cutaneous response to recombinant interleukin 2 in humans immunodeficiency virus 1-seropositive individuals. Proc Nat Acad Sci USA 1990; 87: 5783-7.
43. Kovacs JA, Baseler M, Dewar RJ, et al. Increases in CD4 T lymphocytes with intermittent courses of interleukin-2 in patients with human immunodeficiency virus infection. A preliminary study. N Engl J Med 1995; 332: 567-75.
44. Mellors JW, Rinaldo CR Jr, Gupta P, White RM, Todd JA, Kingsley LA. Prognosis in HIV-1 infection predicted by the quantity of virus in plasma. Science 1996; 272: 1157-70.
45. Kovacs JA, Vogel S, Albert, JM, et al. Controlled trial of interleukin-2 infusions in patients infected with the human immunodeficiency virus. N Engl J Med 1996; 335: 1350-6.
46. Connors M, Kovacs JA, Krevat S, et al. HIV infection induces changes in CD4+ T-cell phenotype and depletions within the CD4+ T-cell reprtoire that are not immediately restored by antiviral or immune-based therapies. Nature Med 1997; 3: 533-40.
47. Loetscher P, Seitz M, Baggiolini M, Moser B. Interleukin-2 regulates CC chemokine receptor expression and chemotactic responsiveness in T lymphocytes. J Exp Med 1996; 184: 569-77.